Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (128)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
  7. Research Letter (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (287)
  2. Breast Medicine Service (287)
  3. Department of Medicine (287)
  4. GSK Faculty (287)
  5. Human Oncology and Pathogenesis Program (287)
  6. Solid Tumor Oncology Division (287)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (58)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (17)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer
    Meeting Abstract

    Sharifi, N.; Kruse, M. L.; McManus, J.; Chung, Y. M.; Wei, W.; Bazeley, P.; Nakamura, F.; Hardaway, A.; Kelley, E. D.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer
    Meeting Abstract

    Ferraro, E.; Razavi, P.; Chandarlapaty, S.; Modi, S.; Wen, H. Y.; Brogi, E.; Norton, L.; Robson, M. E.; Dang, C. T.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Journal Article

    Smith, A. E.; Ferraro, E.; Safonov, A.; Morales, C. B.; Lahuerta, E. J. A.; Li, Q.; Kulick, A.; Ross, D.; Solit, D. B.; de Stanchina, E.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC)
    Meeting Abstract

    Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S.; Boni, V.; Pelekanou, V.; Ternè€s, N.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+ / human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer
    Meeting Abstract

    Campone, M.; Bardia, A.; Kabos, P.; Chandarlapaty, S.; Neven, P.; Boni, V.; Lord, S.; Cartot-Cotton, S.; Celanovic, M.; Gosselin, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer
    Journal Article

    Kruse, M. L.; Patel, M.; McManus, J.; Chung, Y. M.; Li, X.; Wei, W.; Bazeley, P. S.; Nakamura, F.; Hardaway, A.; Downs, E.; more...
    JCI Insight (2021)

    Fulltext@MSK | Save
  • Defining the energetic basis for a conformational switch mediating ligand-independent activation of mutant estrogen receptors in breast cancer
    Journal Article

    Mayne, C. G.; Toy, W.; Carlson, K. E.; Bhatt, T.; Fanning, S. W.; Greene, G. L.; Katzenellenbogen, B. S.; Chandarlapaty, S.; Katzenellenbogen, J. A.; Tajkhorshid, E.
    Molecular Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Unlocking the potential of antibody - Drug conjugates for cancer therapy
    Review

    Drago, J. Z.; Modi, S.; Chandarlapaty, S.
    Nature Reviews Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
    Journal Article

    Brannon, A. R.; Jayakumaran, G.; Diosdado, M.; Patel, J.; Razumova, A.; Hu, Y.; Meng, F.; Haque, M.; Sadowska, J.; Murphy, B. J.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save